PET Imaging of Subjects Using 124I-PU-AD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

EARLY_PHASE1

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-30

Study Completion Date

2019-06-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent 124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or myeloma) and/or Alzheimer's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

NCT01269593

Non-Hodgkin's Lymphoma Myeloma Active Solid Malignancy

ACTIVE_NOT_RECRUITING EARLY_PHASE1

In-Room PET in Proton Radiation Therapy

NCT01228448

Brain Tumor Head and Neck Tumor Skull Base Tumor

COMPLETED NA

PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

NCT01266096

Newly Diagnosed or Recurrent Metastatic Melanoma Patients Malignant Brain Tumors

ACTIVE_NOT_RECRUITING NA

The Utility of PET/CT in the Planning of Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer

NCT00380666

Non-small Cell Lung Cancer

WITHDRAWN NA

PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer

NCT03146117

PET CT

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This first in-human trial of the positron-emitting agent 124I-PU-AD is an open-label pilot (microdose) study. Up to 10 evaluable subjects who have active disease will be enrolled to evaluate the PK, metabolism, biodistribution, and radiation dosimetry of 124I-PU-AD.

Following a 28-day screening period, eligible subjects will return to the clinic on Day 1. A single dose of 124I-PU-AD will be administered by intravenous (IV) injection to subjects.

After 124I-PU-AD tracer injection, PET scans will be performed at 4 time points. At each time-point, an axial body image is acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. Serial blood samples will also be obtained at multiple time points.

Subjects will be evaluated to ensure that there are no clinically significant ongoing AEs prior to discharge.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma Solid Malignancy Alzheimer Disease Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

124I-PU-AD

A single dose of 124I-PU-AD will be administered by intravenous (IV) injection

Group Type EXPERIMENTAL

PU-AD

Intervention Type DRUG

PET Scan

Intervention Type DEVICE

Blood Draws

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PU-AD

Intervention Type DRUG

PET Scan

Intervention Type DEVICE

Blood Draws

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects with a diagnosis of cancer and/or Alzheimer's Disease, meeting trial eligibility criteria as specified below for either disease:

Cancer:
1. Subjects with eligible histologic types of cancer. Eligible histologic types of cancer include solid malignancy, myeloma, and lymphoma.
2. Cancer histology confirmed by pathology.
3. Cancerous disease is radiologically-measurable or evaluable as defined by published tumor response criteria (including but not limited to RECIST 1.1).

Alzheimer's:
1. Established diagnosis of mild-moderate Alzheimer's disease based upon neurological and neuropsychological evaluation following the National Institute on Aging - Alzheimer's disease Association criteria that recently revisited the NINCDS-ADRDA criteria.
2. Documentation of diagnosis of mild-moderate Alzheimer's disease, as above, by board-certified neurologist.
2. Subjects who have both cancer and Alzheimer's Disease, subjects are considered eligible if they meet all eligibility requirements for either Alzheimer's Disease or cancer patients, as specified above.

Exclusion Criteria

1. Subject has unacceptable pre-study organ function during screening defined as:

1. Bilirubin \> 1.5 x institutional upper limit of normal (ULN)
2. AST/ALT \>2.5 x ULN
3. Albumin \< 2 g/dl
4. GGT \> 2.5 x ULN (IF Alkaline phosphatase \> 2.5 x ULN)
5. Creatinine \>1.5 x ULN or creatinine clearance \< 60 mL/min.
2. Subject has history of acute major illness (i.e., unstable cardiovascular condition.)
3. Subject has concurrent participation in any interventional studies within 30 days of first dose of study drug.

Minimum Eligible Age

21 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No